8-K current report · filed Jul 28, 2026

HAEMONETICS CORP (HAE) 8-K Current Report: July 28, 2026

Item 5.07Item 5.02HAE overview

Short answer

HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 5.02 (Departure/Election of Directors or Officers). Martin Madaus elected director effective July 24, 2026, adding healthcare investment and operating expertise.

HAEMONETICS CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Martin Madaus elected director effective July 24, 2026, adding healthcare investment and operating expertise
  • Expected Audit Committee and Governance and Compliance Committee appointments, strengthening oversight roles
  • Shareholder election required at the 2027 annual meeting, making continued board service subject to approval
  • Annual equity award approximately $200,000, aligning compensation with shareholder value
  • Incentive plan expanded by 4,680,000 shares and extended through 2036, creating potential dilution but supporting long-term retention

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • 92.53% quorum; all eight director nominees elected for one-year terms ending 2027
  • Executive compensation received advisory approval, 39,212,253 for versus 572,620 against
  • Ernst & Young LLP ratified as independent auditor for fiscal year ending April 3, 2027
  • 2019 Long-Term Incentive Compensation Plan amendment approved, 37,730,923 votes for
  • 2007 Employee Stock Purchase Plan amendment approved, 39,766,894 votes for

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other HAEMONETICS CORP 8-K filings

Get the next HAE 8-K as it lands

Follow HAE for push alerts, or ask the research agent what this filing means.